ClinicalTrials.gg
RecruitingNCT06765863LIFT-UP RCTUpdated Jan 21, 2026

LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk

An interventional study of Human Milk Fortifier and Volume targets in Very Preterm Infant and Very Low Birthweight, sponsored by Harvard School of Public Health (HSPH). Recruiting at 4 sites in India. Open to participants aged Up to 48 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Harvard School of Public Health (HSPH) · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
Up to 48 Hours
Sex
All
01

Study summary

The goal of the LIFT-UP randomized controlled trial is to evaluate the efficacy of feeding routinely and fortified human milk using a standardized clinical protocol to very low birthweight (VLBW) or very preterm (VPT) infants in the NICU compared to not feeding routinely fortified human milk using the standardized clinical protocol.

The primary research question is: Will VLBW or VPT infants in the NICU who are fed fortified human milk using a standardized feeding protocol have better growth outcomes by facility discharge and at 3 months of age, less illness by discharge, and decreased mortality by discharge and at one month compared to those who are not routinely fed fortified human milk using the same feeding protocol?

Read the detailed description

AIM: To improve feeding and growth outcomes among very low birthweight (LBW; ≤1.5kg) or very preterm (≤32 weeks gestational age) infants admitted to neonatal intensive care units (NICU) in India through fortification of human milk.

OBJECTIVE: To evaluate (via individually randomized controlled study) the efficacy of feeding routinely and fortified human milk using a standardized clinical protocol to very LBW or very preterm infants in the NICU compared to not feeding routinely fortified human milk using the standardized clinical protocol.

STUDY DESIGN This study is a multi-site individually randomized prospective trial among VLBW or VPT infants admitted to the NICU in study facilities who consume human milk and meet eligibility criteria (along with their mothers).

SCREENING AND ENROLLMENT All infants admitted to the NICU and their mothers will be screened for study eligibility. Screening will be performed within 24 hours of birth for inborn infants and within 48 hours of birth for outborn infants. Eligible dyads with the intention to feed human milk [mother's own milk (MOM) or pasteurized donor human milk (PDHM)] whose mothers provide consent will be enrolled into the study.

Once the mother-infant dyad is enrolled and prior to randomization, they will:

Receive the guideline-driven standard of care and be provided access to breast pumps to help initiate and advance breast milk feeding. The guideline-driven standard of care includes facility-based lactation support/feeding counseling + KMC + WASH components designed specifically for small vulnerable newborns and was developed as part of a different study protocol (see NCT06390943).

Adhere to a clinical guideline including targets for initiating and advancing breast milk feeding. Initially, this clinical guideline will help infants achieve breast milk volume intake of at least 60 mL/kg/day, the primary criterion for randomization. After randomization, the clinical guideline will continue to support advancing human milk feeding for all infants advance to 180 mL/kg/day.

RANDOMIZATION Once an infant consumes at least 60 mL/kg/day of breast milk, enrolled dyads will be assessed for eligibility for randomization. Eligible dyads will be randomized individually in a 1:1 ratio to either the intervention or comparison arm. Randomization sequences will be previously generated by the study statistician. If an infant does not consume at least 60 mL/kg/day of breastmilk by day 10 of chronological age, the mother-infant dyad will be administratively withdrawn from the study.

DELIVERY OF INTERVENTION Mothers of infants randomized to the intervention arm will express their breast milk into a standardized measurement cup (or PDHM can be used). Clinical research staff will mix human milk fortifier (HMF) in human milk (either MOM or PDHM, if available) per manufacturer specifications per feed for a minimum of 21 days.

Dyads in both arms will continue to receive the guideline-driven standard of care, access to breast pumps, and follow the volume target and trajectory protocol until they meet stopping criteria. Data will be collected every 24 hours, including a log at every feed, regardless of study arm assignment.

If an infant in either arm does not meet protocolized minimum volume targets or trajectories AND that infant meets weight-based safety net criteria, clinicians will intervene per judgment aligned with national and local protocols.

The intervention will not be continued once the infant meets stopping criteria with the goal of the infant having fully transitioned to exclusive breast milk feeding by then.

STOPPING CRITERIA After the minimum duration of 21 days post-randomization, hospitalized infants should continue to receive volume targeted feeding with or without HMF for as long as they receive expressed breast milk. Once infants transition to full, direct breastfeeding in preparation for discharge or are being discharged per clinician discretion, they will stop adhering to the volume targets and infants in the intervention group will stop receiving fortified human milk.

DISCHARGE FROM FACILITY TO HOME After stopping criteria are met, routine clinical care around infant feeding will be provided. Infants can be discharged home when deemed clinically appropriate per facility protocols and clinician judgment. The guideline-driven standard of care will encourage all mothers to exclusively breastfeed their infants prior to discharge and to continue doing so after discharge.

POST-DISCHARGE FACILITY VISITS All dyads will be followed up at 2 weeks of age, 4 weeks of age, and 3 months of chronological age.

02

Conditions studied

  • Very Preterm Infant
  • Very Low Birthweight

Browse trials for

Keywords

  • very preterm
  • very low birthweight
  • fortification
  • human milk
03

In context

Birth Weight

185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.

This study's planned enrollment of 776 is above the median of 170 across 117 interventional studies indexed under Birth Weight.

Browse Birth Weight studies →

Lead sponsor

Harvard School of Public Health (HSPH) is the lead sponsor of 154 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 48 Hours
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Very LBW (≤1.5kg)* or very preterm (≤32 weeks) infants admitted to NICU at study facility within 24 hours of birth for in-born infants and up to 48 hours for out-born**
  • Mother and infant alive during screening
  • Mother age 18+ years
  • Lives within catchment areas of the facility
  • Mother intends to stay in catchment area of the study facility for at least 3 months
  • At randomization: Infant receiving at least 60 mL/kg/day of human milk***

Exclusion criteria

Exclusion Criteria:

  • Lives outside the defined catchment area
  • Congenital abnormalities or acquired conditions that interfere with feeding or placement of nasogastric/orogastric tube [cleft lip/palate, toxoplasmosis, other agents, rubella, cytomegalovirus, and herpes (TORCH), Trisomy 21, congenital cardiac defect, neural tube defect, gastrointestinal tract anomalies, hydrocephalus, NEC]
  • Severe birth asphyxia
  • Critically ill (i.e. not on enteral feeds)
  • Unknown date of birth and unknown gestational age
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
776 participants (estimated)

Study arms

  • Experimental
    Routine fortification of human milk with human milk fortifier using a standardized clinical protocol

    Enrolled participants in the intervention arm will be exposed to: * Provision of guideline-driven standard of care specifically for VPT/ VLBW babies * Encouragement to express breast milk with breast pumps * Adherence to a clinical guideline including targets for initiation and advancement of breast milk feeding for VPT/ VLBW babies based on birthweight * Fortification of human milk with HMF * Adherence to standardized stopping criteria (i.e., stopping adherence to clinical feeding guideline AND stopping routine fortification of human milk)

    Dietary Supplement: Human Milk Fortifier · Other: Volume targets

  • Active comparator
    No routine fortification of human milk using a standardized clinical protocol

    Participants in the control group will have the same exposures as the participants in the intervention group EXCEPT for the human milk consumed will not be fortified with HMF. * Provision of guideline-driven standard of care specifically for VPT/ VLBW babies * Encouragement to express with breast pumps * Adherence to a clinical guideline including targets for initiation and advancement of breast milk feeding for VPT/ VLBW babies based on birthweight * Adherence to standardized stopping criteria (i.e., stopping adherence to clinical feeding guideline)

    Other: Volume targets

Interventions

  • Dietary supplementHuman Milk Fortifier

    Human milk fortifier added to expressed human milk (mother's own milk or pasteurized donor human milk) per feed per manufacturer's instructions for a minimum of 21 days (in-facility provision only) * Clinical feeding guideline including targets for initiation and advancement of breast milk feeding * Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]

    Also known as: Volume targets, Guideline-driven standard of care

  • OtherVolume targets

    * Clinical feeding guideline including targets for initiation and advancement of breast milk feeding * Provision of guideline-driven standard of care \[facility-based lactation support/feeding counseling + KMC + WASH package (referred to as facility-based FSP+) and breast pumps\]

    Also known as: Guideline driven standard of care

06

What researchers measure

Primary outcomes

  1. Length-for-age Z score (LAZ)

    Mean LAZ (SD, range) measured at birth, 2 weeks, 4 weeks and 3 months of age

    Time frame: 3 Months

Secondary outcomes

  1. Length of Stay

    Mean (SD) number of days admitted in the study facility from randomization to facility discharge

    Time frame: From date of randomization until the date of facility discharge or date of death from any cause, whichever came first, assessed up to 3 months of age.

  2. Feeding intolerance

    % infants identified with feeding intolerance

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

  3. Weight growth velocity

    % infants attaining 15 g/kg/day

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

  4. Length gain

    Mean (SD) change in length (mm/week)

    Time frame: From randomization to facility discharge, assessed up to 3 months of age.

  5. Head circumference gain

    Mean (SD) change in head circumference (mm per week)

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

  6. Necrotizing enterocolitis (NEC)

    % infants diagnosed with NEC

    Time frame: From randomization to facility discharge, assessed up to 3 months of age.

  7. Sepsis/possible serious bacterial infection (PSBI)

    % diagnosed with sepsis or possible serious bacterial infection (PSBI)

    Time frame: From randomization to facility discharge, assessed up to 3 months of age

  8. Infant mortality

    % infants died

    Time frame: From randomization to 3 months of age

  9. Birthweight regain

    % infants who regain birthweight by 2 weeks of age

    Time frame: 2 weeks of age

  10. Mean weight growth velocity (4 weeks)

    Mean (SD) change in weight (growth) at 4 weeks of age

    Time frame: From randomization to 4 weeks of age

  11. Neonatal mortality (4 weeks)

    % of neonates who died up to 4 weeks of age

    Time frame: From randomization to 4 weeks of age

  12. Sepsis/possible serious bacterial infection (PSBI, 4 weeks)

    % of infants diagnosed with sepsis/PSBI up to 4 weeks of age

    Time frame: From randomization to 4 weeks of age

  13. Mean weight growth velocity

    Mean change in infant weight (growth) calculated in grams/kilogram/day (g/kg/day)

    Time frame: From randomization to facility discharge, assessed up to 3 months of age.

  14. Weight-for-age Z score (WAZ)

    Mean (SD) WAZ at 3 months of age

    Time frame: 3 months of age

  15. Weight-for-length Z score (WLZ)

    Mean (SD) weight-for-length Z score (WLZ) at 3 months of age

    Time frame: 3 months of age

  16. Head circumference-for-age Z score (HcAZ)

    Mean (SD) HcAZ

    Time frame: 3 months of age

  17. Change in WAZ

    Change in WAZ from randomization to 3 months of age

    Time frame: From randomization to 3 months of age

  18. Change in LAZ

    Change in LAZ from randomization to 3 months of age

    Time frame: From randomization to 3 months of age

07

Study locations

3 of 4 sites recruiting
  • Ballari Medical College and Research Centre
    Ballary, Karnataka, India
    Recruiting
    • Durgappa, MD · Contact
  • KLES Dr Prabhakar Kore Hospital & Medical Research Center
    Belagavi, Karnataka, India
    Not yet recruiting
    • Roopa Bellad, MD · Contact
    • Roopa Bellad, MD · Principal investigator
    • Sunil S Vernekar · Sub investigator
    • S M Dhaded · Sub investigator
  • JJM Medical College
    Davangere, Karnataka, India
    Recruiting
    • Gowdar Guruprasad, MD, DCH, DNB, DM · Contact
  • Niloufer Hospital
    Hyderabad, Telangana, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified datasets will be released after the close of the project in a data sharing repository, such as Harvard Dataverse or similar, in a format readable by analytics tools. Harvard Dataverse is an online data repository where you can share, preserve, cite, explore, and analyze research data. Datasets and data dictionaries will be provided in compliance with the ethical review board requirements. As part of the Harvard Dataverse system, registration to download datasets is required. External partners (those not involved in the study) must provide their contact information and describe their intention of data use.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Study data will be available after study completion, expected in mid-2027.

Access criteria: Data will be available on Harvard Dataverse and users will register for access stating their intent to use the data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Of 43 non-industry interventional studies with no phase under Birth Weight, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 36. This study's planned 26 months is above that.

Counting every sponsor, half of 44 studies reached it within 19 months; a quarter within 15 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 9, 2025
StartActual
Jan 16, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06765863
Collaborators
Boston Children's Hospital, Brigham and Women's Hospital, Emory University, Muhimbili University of Health and Allied Sciences, Jawaharlal Nehru Medical College, PATH, University of North Carolina
Responsible party
Katherine Semrau (Deputy Director, Ariadne Labs & Director, BetterBirth Program; Associate Professor, HSPH, Harvard School of Public Health (HSPH)) — Principal investigator
First posted
Jan 9, 2025
Start date
Jan 16, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Ilana Dzuba, MHS
Contact
idzuba@ariadnelabs.org
617-384-6555
Linda Vesel, PhD, MPH
Contact
lvesel@ariadnelabs.org
Katherine Semrau, PhD, MPH
principal investigator · Ariadne Labs | Harvard TH Chan School of Public Health and Brigham and Womens Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion